SCHEMBL4892358

SCHEMBL4892358

COc1nc(N)c(C(=O)OC(C)(C)C)n1-c1ccc(F)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
LMNA P02545 3/20 0.34
MAPT P10636 2/20 0.34
HSP90AA1 P07900 1/20 0.34
NTSR1 P30989 1/20 0.34
HTT P42858 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
HPGD P15428 1/20 0.33
HIF1A Q16665 1/20 0.33
DHFR P00374 1/20 0.33
FPR2 P25090 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895668 0.83 MAPK1 (0.38) MAPK1KDM4EL3MBTL1LMNAALDH1A1
SCHEMBL4893158 0.82 MAPK1 (0.40) MAPK1KDM4ELMNAMAPTMEN1
SCHEMBL4859820 0.82 MAPK1 (0.42) MAPK1L3MBTL1CNR1CNR2LMNA
SCHEMBL4894672 0.77 MAPK14 (0.34) MAPK1KDM4EL3MBTL1CNR1CNR2
SCHEMBL3289003 0.75 MAPK1 (0.40) MAPK1KDM4EL3MBTL1LMNAMAPT
SCHEMBL4897706 0.74 MAPK1 (0.40) MAPK1KDM4EL3MBTL1LMNAMAPT
SCHEMBL4786438 0.73 CNR1 (0.43) L3MBTL1CNR1CNR2LMNAMAPT
SCHEMBL4891117 0.72 ENPP2 (0.40) KDM4EMAPTTHRBGRM5
SCHEMBL4897672 0.71 FFAR2 (0.40) L3MBTL1LMNAMAPTALDH1A1GAA
SCHEMBL3231306 0.70 MAPK1 (0.56) MAPK1KDM4EL3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130313-A1 IMIDAZOLE DERIVATIVES AS MODULATORS OF THE GABA RECEPTOR FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 ASTRAZENECA AB (SE) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262064-A1 Novel Compounds For The Treatment Of GI Disorders 682 GABRB2, GABRA2, GABBR2 MAPK1 3674/4885KDM4E 2374/4885L3MBTL1 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.